BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34198358)

  • 1. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
    Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
    Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
    Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
    Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
    Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
    Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
    Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
    Yen FS; Lai JN; Wei JC; Chiu LT; Hwu CM; Hou MC; Hsu CC
    PLoS One; 2020; 15(12):e0243783. PubMed ID: 33315940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin and the Development of Asthma in Patients with Type 2 Diabetes.
    Yen FS; Hsu CC; Shih YH; Pan WL; Wei JC; Hwu CM
    Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.
    Yen FS; Yang YC; Hwu CM; Wei JC; Huang YH; Hou MC; Hsu CC
    Liver Int; 2020 May; 40(5):1089-1097. PubMed ID: 31960563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
    Vilar-Gomez E; Calzadilla-Bertot L; Wong VW; Castellanos M; Aller-de la Fuente R; Eslam M; Wong GL; George J; Romero-Gomez M; Adams LA
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):136-145.e6. PubMed ID: 32389886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes.
    Yen FS; Wei JC; Shih YH; Hsu CC; Hwu CM
    Sci Rep; 2022 Feb; 12(1):3270. PubMed ID: 35228620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
    Vilar-Gomez E; Vuppalanchi R; Desai AP; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
    Aliment Pharmacol Ther; 2019 Aug; 50(3):317-328. PubMed ID: 31157422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes.
    Yen FS; Hsu CC; Hu KC; Hung YT; Hsu CY; Wei JC; Hwu CM
    Int J Environ Res Public Health; 2022 Sep; 19(17):. PubMed ID: 36078769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.
    Huynh DJ; Renelus BD; Jamorabo DS
    BMC Gastroenterol; 2023 Dec; 23(1):450. PubMed ID: 38114915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis.
    Yen FS; Hou MC; Wei JC; Shih YH; Hsu CY; Hsu CC; Hwu CM
    Front Pharmacol; 2022; 13():1049094. PubMed ID: 36618937
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.
    Yen FS; Hou MC; Wei JC; Shih YH; Hwu CM; Hsu CC
    BMC Med; 2024 Jan; 22(1):8. PubMed ID: 38172833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.
    Hung SC; Chang YK; Liu JS; Kuo KL; Chen YH; Hsu CC; Tarng DC
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):605-14. PubMed ID: 26094107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes.
    Yen FS; Wei JC; Shih YH; Pan WL; Hsu CC; Hwu CM
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design.
    Yen FS; Chen W; Wei JC; Hsu CC; Hwu CM
    PLoS One; 2018; 13(10):e0204859. PubMed ID: 30286138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study.
    Tseng CH
    Front Endocrinol (Lausanne); 2022; 13():1036885. PubMed ID: 36277720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.